InMed Pharmaceuticals (INM) Share-based Compensation (2019 - 2026)
InMed Pharmaceuticals' (INM) quarterly Share-based Compensation came in at $109344.0 in Q1 2026, up 370.29% year-on-year from $23250.2 in Q1 2025, and up 532.81% quarter-over-quarter from -$25264.0 in Q4 2025.
InMed Pharmaceuticals (INM) Share-based Compensation (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Share-based Compensation history runs 8 years deep, the most recent figure standing at $109344.0 for Q1 2026.
- On a quarterly basis, Share-based Compensation rose 370.29% year-over-year to $109344.0 in Q1 2026; TTM through Mar 2026 was $109344.0, a 303.92% increase from a year earlier, with the FY2025 full-year figure at $72549.0, down 47.32% from the prior year.
- Share-based Compensation grew to $109344.0 in Q1 2026 per INM's latest filing, from -$25264.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $195085.0 in Q1 2022 and bottomed at -$413329.0 in Q2 2023.
- The 5-year median for Share-based Compensation is $25191.0 (2023), against an average of $14218.8.
- Across the five-year window, Share-based Compensation plunged 333.67% in 2023 and surged 370.29% in 2026, its largest moves.
- Year by year, Share-based Compensation stood at $70638.0 in 2022, then sank by 74.14% to $18264.0 in 2023, then slumped by 226.8% to -$23159.0 in 2024, then slipped by 9.09% to -$25264.0 in 2025, then surged by 532.81% to $109344.0 in 2026.
- Per Business Quant, the three latest INM Share-based Compensation figures stand at $109344.0 (Q1 2026), -$25264.0 (Q4 2025), and -$20205.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 43.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 25.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 125.69 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 58.30 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 56.50 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 55.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.00 Mn |
| 10 | InMed Pharmaceuticals | 307,858.50 | -4.93 Mn | - | 109,344.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 109,344.00 |
| Mar 31, 2026 | 109,344.00 |
| Dec 31, 2025 | -25,264.00 |
| Dec 31, 2025 | -25,264.00 |
| Sep 30, 2025 | -20,205.00 |
| Sep 30, 2025 | -20,205.00 |
| Jun 30, 2025 | -63,613.00 |
| Jun 30, 2025 | -63,613.00 |
| Mar 31, 2025 | -40,454.00 |
| Mar 31, 2025 | -40,454.00 |
| Dec 31, 2024 | -23,159.00 |
| Dec 31, 2024 | -23,159.00 |
| Sep 30, 2024 | -28,964.00 |
| Sep 30, 2024 | -28,964.00 |
| Jun 30, 2024 | 38,955.00 |
| Jun 30, 2024 | 38,955.00 |
| Mar 31, 2024 | 55,305.00 |
| Mar 31, 2024 | 55,305.00 |
| Dec 31, 2023 | 18,264.00 |
| Dec 31, 2023 | 18,264.00 |